NDA 021179 · Genzyme
Renagel
Sevelamer Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Dec 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Jul 12, 2000
Approved uses
3
Original approval plus efficacy supplements
Registered trials
91
31 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 19, 2007 Supplement 20 · Efficacy LabelLetter
- Feb 6, 2004 Supplement 2 · Efficacy Letter
- Jul 12, 2000 Original approval · Type 3 - New Dosage Form ReviewLabelLetter
2 products under this application
- RENAGEL · SEVELAMER HYDROCHLORIDE 400MG · TABLET, ORAL · Prescription · TE AB
- RENAGEL · SEVELAMER HYDROCHLORIDE 800MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Sevelamer" as an intervention, any sponsor and status, largest first.
- Dialysis Clinical Outcomes Revisited (DCOR) TrialPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00324571 · 2,000 participants · Start Mar 2001
Drug: Sevelamer hydrochloride; Calcium-based phosphate binder · For: Chronic Kidney Disease
Sites: Gadsden, Alabama; Huntsville, Alabama; Tucson, Arizona · 73 sites in all
- A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on DialysisPivotal-lookingCompleted
ArdelyxIndustry
NCT03427125 · 1,559 participants · Start Jan 8, 2018 · Primary completion Nov 15, 2019
Drug: Tenapanor; Placebo and 1 more · For: Hyperphosphatemia
Sites: The Bronx, New York; Winston-Salem, North Carolina
- A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis PatientsPivotal-lookingCompleted
Vifor PharmaIndustry
NCT01324128 · 1,059 participants · Start Mar 2011 · Primary completion Apr 2012
Drug: PA21 (2.5 g tablet containing 500 mg iron); Sevelamer carbonate and 1 more · For: Chronic Kidney Disease Requiring Chronic Dialysis
Sites: San Antonio, Texas; Sankt Pölten, Austria; Liège, Belgium · 15 sites in all
- Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer HydrochloridePivotal-lookingTerminated
Ineos Healthcare LimitedIndustry
NCT00844662 · 1,000 participants (planned) · Start Jul 2009 · Primary completion Sep 2011
Drug: Fermagate; Sevelamer hydrochloride · For: Chronic Kidney Failure
Sites: Hot Springs, Arkansas; Bakersfield, California; Lynwood, California · 109 sites in all
- A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis PatientsPivotal-lookingCompleted
Vifor PharmaIndustry
NCT01464190 · 659 participants · Start Sep 2011 · Primary completion Oct 2012
Drug: PA21 (2.5 g tablet containing 500 mg iron); Sevelamer carbonate · For: Chronic Kidney Disease Requiring Chronic Dialysis
Sites: San Antonio, Texas; Sankt Pölten, Austria; Liège, Belgium · 15 sites in all
- A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With HyperphosphatemiaPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT00542815 · 632 participants · Start Nov 2007 · Primary completion Aug 2010
Drug: MCI-196; Another Phosphate binder (Sevelamer) · For: Chronic Kidney Disease; Dialysis; Hyperphosphatemia
Sites: Graz, Austria; Frýdek-Místek, Czechia; Hradec Králové, Czechia · 115 sites in all
- AP301 Efficacy and Safety in Chinese Dialysis Patients With HyperphosphatemiaPivotal-lookingCompleted
Alebund PharmaceuticalsIndustry
NCT07030595 · 474 participants · Start Jun 12, 2023 · Primary completion Oct 2, 2024
Drug: AP301; Sevelamer carbonate (Renvela®) and 1 more · For: ESRD (End Stage Renal Disease); Chronic Kidney Disease(CKD); Hyperphosphatemia and 3 more
Sites: Beijing, China; Jilin City, China; Xiamen, China · 50 sites in all
- A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on DialysisPivotal-lookingCompleted
Keryx BiopharmaceuticalsIndustry
NCT01191255 · 441 participants · Start Oct 2010 · Primary completion Jan 2013
Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo · For: Hyperphosphatemia; Kidney Failure
Sites: Tempe, Arizona; Los Angeles, California; Riverside, California · 56 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- End-stage renal disease.
Abbasi MA, Chertow GM, Hall YN · BMJ Clin Evid 2010 · Systematic Review
- End stage renal disease.
Hall YN, Chertow GM · BMJ Clin Evid 2007 · Systematic Review
- The phosphate binder equivalent dose.
Daugirdas JT, Finn WF, Emmett M, et al. · Semin Dial 2011 · Research Support, N.I.H., Extramural, Systematic Review
- Parathyroidectomy reduces the costs of medication in patients with secondary hyperparathyroidism.
Pereira GMD, Liao M, Arap SS, et al. · Clinics (Sao Paulo) 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Natale P, Green SC, Ruospo M, et al. · Cochrane Database Syst Rev 2025 · Systematic Review, Meta-Analysis
- A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients.
Chertow GM, Dillon M, Burke SK, et al. · Clin Nephrol 1999 · Clinical Trial, Randomized Controlled Trial
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.